Phase 1b/2 RCT in 49 patients with ARDS from viral pneumonia (47 treated): time to clinical improvement did not differ significantly with STSA-1002 1,350 mg or 750 mg vs placebo (6.0, 8.4 vs 7.4 days; SHR 1.55, 95% CI 0.68-3.55); it was well tolerated.
RCTn = 49
Wang et al. Anti-C5a Antibody STSA-1002 for Patients With ARDS Due to Viral Pneumonia: A Phase 1b/2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial